Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | CA4 | P22748 | 1/20 | 0.48 |
| ▸ | KIF11 | P52732 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | CASR | P41180 | 1/20 | 0.43 |
| ▸ | MMP1 | P03956 | 1/20 | 0.43 |
| ▸ | MMP13 | P45452 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31174571 | 0.88 | LTA4H (0.49) | LTA4HKMT2AKIF11KCNH2SIGMAR1 | |
| SCHEMBL10368035 | 0.85 | HTT (0.56) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL11374176 | 0.85 | LTA4H (0.53) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL30887388 | 0.84 | KMT2A (0.62) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL17964411 | 0.83 | LTA4H (0.55) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL11780824 | 0.83 | KIF11 (0.44) | LTA4HKMT2AKIF11KCNH2SIGMAR1 | |
| SCHEMBL9341171 | 0.81 | LTA4H (0.53) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL8592603 | 0.81 | LTA4H (0.53) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL574696 | 0.81 | LTA4H (0.53) | LTA4HKMT2ACA4KIF11KCNH2 | |
| SCHEMBL8976499 | 0.80 | LTA4H (0.52) | LTA4HKMT2ACA4KIF11KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | claimed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | claimed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | claimed |
| US-9938314-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2018-04-10 | — | — | US | claimed |
| EP-3071588-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2016-09-28 | — | — | EP | claimed |
| WO-2015077292-A1 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | SOMALOGIC, INC. (US) | 2015-05-28 | — | — | WO | claimed |
| JP-4623828-B2 | — | — | 2011-02-02 | — | — | JP | claimed |
| EP-1102782-B1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2006-03-29 | — | — | EP | claimed |
| EP-1102782-A4 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2002-01-30 | — | — | EP | claimed |
| US-6335432-B1 | FOR FLUORESCENT HYBRIDIZATION PROBES FOR USE IN DIAGNOSIS, RESEARCH, AND THERAPY | BIO-RED LABORATORIES, INC. | 2002-01-01 | — | — | US | claimed |
| EP-1102782-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | Bio-Rad Laboratories (US) | 2001-05-30 | — | — | EP | claimed |
| WO-2000008041-A9 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2001-02-01 | — | — | WO | claimed |
| WO-2000008041-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO-RAD LABORATORIES (US) | 2000-02-17 | — | — | WO | claimed |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | SOMALOGIC, INC. (US) | 2019-03-26 | — | — | US | disclosed |
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | SOMALOGIC OPERATING CO. INC. | 2018-07-19 | — | — | US | disclosed |
| EP-3330277-A2 | CYTIDINE-5-CARBOXAMIDE MODIFIED NUCLEOTIDE COMPOSITIONS AND METHODS RELATED THERETO | Somalogic, Inc. (US) | 2018-06-06 | — | — | EP | disclosed |
| US-6335432-B1 | FOR FLUORESCENT HYBRIDIZATION PROBES FOR USE IN DIAGNOSIS, RESEARCH, AND THERAPY | BIO-RED LABORATORIES, INC. | 2002-01-01 | — | — | US | disclosed |
| EP-1102782-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | Bio-Rad Laboratories (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000008041-A9 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO RAD LABORATORIES (US) | 2001-02-01 | — | — | WO | disclosed |
| WO-2000008041-A1 | STRUCTURAL ANALOGS OF AMINE BASES AND NUCLEOSIDES | BIO-RAD LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180201641-A1 | Cytidine-5-Carboxamide Modified Nucleotide Compositions and Methods Related Thereto | NT5C3B, CDA, RNGTT | LTA4H 2776/4885KMT2A 685/4885CA4 1615/4885 |
| US-10239908-B2 | Cytidine-5-carboxamide modified nucleotide compositions and methods related thereto | NT5C3B, CDA, RNGTT | LTA4H 2776/4885KMT2A 685/4885CA4 1615/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.